GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioasis Technologies Inc (OTCPK:BIOAF) » Definitions » Cyclically Adjusted PB Ratio

Bioasis Technologies (Bioasis Technologies) Cyclically Adjusted PB Ratio : 0.20 (As of Apr. 29, 2024)


View and export this data going back to 2009. Start your Free Trial

What is Bioasis Technologies Cyclically Adjusted PB Ratio?

As of today (2024-04-29), Bioasis Technologies's current share price is $0.004. Bioasis Technologies's Cyclically Adjusted Book per Share for the quarter that ended in Nov. 2022 was $0.02. Bioasis Technologies's Cyclically Adjusted PB Ratio for today is 0.20.

The historical rank and industry rank for Bioasis Technologies's Cyclically Adjusted PB Ratio or its related term are showing as below:

BIOAF's Cyclically Adjusted PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.74
* Ranked among companies with meaningful Cyclically Adjusted PB Ratio only.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Bioasis Technologies's adjusted book value per share data for the three months ended in Nov. 2022 was $-0.025. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $0.02 for the trailing ten years ended in Nov. 2022.

Shiller PE for Stocks: The True Measure of Stock Valuation


Bioasis Technologies Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Bioasis Technologies's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioasis Technologies Cyclically Adjusted PB Ratio Chart

Bioasis Technologies Annual Data
Trend Feb13 Feb14 Feb15 Feb16 Feb17 Feb18 Feb19 Feb20 Feb21 Feb22
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.18 6.46 4.63 8.86 7.61

Bioasis Technologies Quarterly Data
Feb18 May18 Aug18 Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.22 7.61 5.65 5.62 6.76

Competitive Comparison of Bioasis Technologies's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Bioasis Technologies's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bioasis Technologies's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bioasis Technologies's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Bioasis Technologies's Cyclically Adjusted PB Ratio falls into.



Bioasis Technologies Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Bioasis Technologies's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.004/0.02
=0.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bioasis Technologies's Cyclically Adjusted Book per Share for the quarter that ended in Nov. 2022 is calculated as:

For example, Bioasis Technologies's adjusted Book Value per Share data for the three months ended in Nov. 2022 was:

Adj_Book=Book Value per Share/CPI of Nov. 2022 (Change)*Current CPI (Nov. 2022)
=-0.025/125.6074*125.6074
=-0.025

Current CPI (Nov. 2022) = 125.6074.

Bioasis Technologies Quarterly Data

Book Value per Share CPI Adj_Book
201302 0.089 97.953 0.114
201305 0.090 98.282 0.115
201308 0.073 98.675 0.093
201311 0.068 98.334 0.087
201402 0.052 99.057 0.066
201405 0.043 100.373 0.054
201408 0.064 100.352 0.080
201411 0.051 99.635 0.064
201502 0.036 99.032 0.046
201505 0.031 100.333 0.039
201508 0.022 100.548 0.027
201511 0.015 100.135 0.019
201602 0.027 100.040 0.034
201605 0.024 101.355 0.030
201608 0.016 101.617 0.020
201611 0.011 101.829 0.014
201702 0.006 102.779 0.007
201705 0.055 103.256 0.067
201708 0.047 103.587 0.057
201711 0.034 104.072 0.041
201802 0.007 105.052 0.008
201805 0.025 106.148 0.030
201808 0.001 106.383 0.001
201811 0.005 106.338 0.006
201902 -0.007 106.649 -0.008
201905 -0.008 108.048 -0.009
201908 -0.020 108.245 -0.023
201911 -0.021 108.519 -0.024
202002 -0.029 109.139 -0.033
202005 -0.030 108.175 -0.035
202008 -0.006 109.662 -0.007
202011 0.004 109.793 0.005
202102 0.004 110.968 0.005
202105 -0.001 113.576 -0.001
202108 -0.003 115.421 -0.003
202111 -0.017 117.269 -0.018
202202 -0.021 119.703 -0.022
202205 -0.021 123.323 -0.021
202208 -0.017 124.958 -0.017
202211 -0.025 125.607 -0.025

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Bioasis Technologies  (OTCPK:BIOAF) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Bioasis Technologies Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Bioasis Technologies's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Bioasis Technologies (Bioasis Technologies) Business Description

Traded in Other Exchanges
N/A
Address
157 Church Street, 19th Floor, New Haven, CT, USA, 06510
Bioasis Technologies Inc is a development stage biopharmaceutical company. It is engaged in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. The company has worked on a blood-brain barrier program and studies disorders in the brain. The company's xB3 program describes its proprietary carrier, for the delivery of therapeutics across the blood-brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The company's in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.

Bioasis Technologies (Bioasis Technologies) Headlines